Senseonics Holdings, Inc. · NASDAQ:SENS
Senseonics — Guggenheim MedTech Disruptors Summit 2019
16 slides from Senseonics's conference presentation, May 29, 2019
Slide 1: Past, Present and Future
PAST, PRESENT AND FUTURE Guggenheim MedTech Disruptors Summit May 29 2019 FOR INVEST OR S ONLY | Guggenheim MedTech Disruptors Summit 2019
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that are not purely historical regarding Senseonics’ or its management’s intentions, beliefs, expectations and strategies for the future. All forward-looking statements and reasons why results might differ included in t
Slide 3: Senseonics Past
SENSEONICS PAST: Almost 20 years to develop the technology, 4 years of pivotal studies to gain US and OUS approval 50% YOY 1996 1997 2009 2010 2013 2015 2016 2017 Founded Patented first First 1 to 6-month System PRECISE CE marking PRECISE II fluorescent successful sensor Validation demonstrated for
Slide 4: Senseonics Present
SENSEONICS PRESENT: Almost 20 years to develop the technology, 4 years of pivotal studies to gain US and OUS approval 50% YOY 1996 1997 2009 2010 2013 2015 2016 2017 Founded Patented first First 1 to 6-month System PRECISE CE marking PRECISE II fluorescent successful sensor Validation demonstrated f
Slide 5: Our Countries
OUR COUNTRIES FOR INVEST OR S ONLY | Guggenheim MedTech Disruptors Summit 2019 5
Slide 6: The Eversense CGM System
THE EVERSENSE® CGM SYSTEM EVERSENSE CLOUD SENSOR SMART EVERSENSE APP EVERSENSE NOW + Fully implanted TRANSMITTER + Real-time readings + Share capability + Small size + On-body vibe alerts every 5 mins + Up to 180 days + Removable/ + No extra receiver rechargeable + Trends, threshold and + Gentle adh
Slide 7: Evidence Build and EU Clinical Practice Guidelines
EVIDENCE BUILD AND EU CLINICAL PRACTICE GUIDELINES FOR INVEST OR S ONLY | Guggenheim MedTech Disruptors Summit 2019 7
Slide 8: Abstracts and Publications 2019-2019
ABSTRACTS AND PUBLICATIONS 2019-2019 FOR INVEST OR S ONLY | Guggenheim MedTech Disruptors Summit 2019 8
Slide 9: Abstracts and Publications 2019-2019
ABSTRACTS AND PUBLICATIONS 2019-2019 PUBLICATIONS in Review Long-Term Safety of an Implantable Continuous Glucose Sensor: A Post-Market Registry Study Dorothee Deiss, Concetta Irace, Grace Carlson, Katherine S. Tweden, Francine R. Kaufman Real-World Data from the First US Commercial Eversense Users
Slide 10: Value of CGM
VALUE OF CGM • Improves diabetes outcomes and facilitates diabetes management GCM Fastest Growing Segment* • Provides retrospective data $5 ~$2.2B 50% YOY • First line technology ~$3.0 Revenue In Billions ($) $4 • Integrates with pumps, pens and $3 $2.0 U.S. MARKET algorithms $1.7 • Growth of market
Slide 11: What Makes Eversense a CGM of Choice
WHERE OUR PRESENT PATIENTS WHAT MAKES ARE IN THE CGM CONTINUUM – EVERSENSE A Eversense is meeting the needs of patients using other CGMs CGM OF CHOICE • Long-term • Implanted • On-body vibration • Accuracy • Flexibility • Data management • Safety FOR INVEST OR S ONLY | Guggenheim MedTech Disruptors
Slide 12: First Look at US Patient Data
FIRST LOOK AT US PATIENT DATA Glucometric data on the first 205 patients who completed 90 days from sensor insertion ~1/3 CGM naïve, ~80% T1D n=205 90 day analysis Percent Wear of Transmitter Mean Sensor Glucose mg/dL 161.76 (33.33) Median wear 83.74 % of time From total population (n=205) Mean SD m
Slide 13: 180 Day Clinical Trial: The PROMISE Study
180 DAY CLINICAL TRIAL : THE PROMISE STUDY FOR INVEST OR S ONLY | Guggenheim MedTech Disruptors Summit 2019 13
Slide 14: Product Strategy
PRODUCT STRATEGY • Extend wear • Reduce/near eliminate calibrations • Improve on-body footprint • Pediatric indication • Enhance partnerships and integrate as iCGM with AP, CSII, Pens • Decision support • Type 2 strategy FOR INVEST OR S ONLY | Guggenheim MedTech Disruptors Summit 2019 14
Slide 15: Eversense Pipeline (Future)
EVERSENSE PIPELINE (FUTURE) 1 2 3 365-DAY AUTONOMOUS ON-DEMAND: TYPE 1: SENSOR LIFE: SENSING TYPE 2 GEMINI 1x/week calibration Battery integration FGM FGM +CGM additional analytes long-term wear w/ no flash when desired transmitter CGM for peace of mind Same sensor technology. Expanded opportunities
Slide 16: Thank You
THANK YOU FOR INVEST OR S ONLY | Guggenheim MedTech Disruptors Summit 2019
Senseonics Holdings — Guggenheim MedTech Disruptors Summit 2019 on 6ix